Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab vs. Secukinumab in Elderly Psoriasis
NCT06811558Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Feb 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
01
Overview
Randomised trial in plaque psoriasis comparing Ixekizumab Group with Secukinumab Group (2 arms). Primary endpoints: Proportion of subjects achieving PASI 90 at 16 weeks and Proportion of subjects achieving sPGA 0 or 1 at 16 weeks. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
ixekizumabsecukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06811558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06811558.